# Tirzepatide vs Semaglutide 1 mg: UK Cost per Patient Reaching Target

A UK cost-to-target analysis in type 2 diabetes | tirzepatide cost £5,650 to £9,462 less than semaglutide 1 mg per patient reaching the strictest composite, and more at the loosest target.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/cost-per-patient-who-actually-hits-target
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Tirzepatide vs Semaglutide 1 mg: UK Cost per Patient Reaching Target

Dividing annual cost by response rate put tirzepatide £5,650 to £9,462 lower per patient reaching the strictest target. The comparison used semaglutide 1 mg in adults with type 2 diabetes.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Lower cost per patient reaching target · vs semaglutide 1 mg, one year, GBP · tirzepatide 5 mg · £5,650 · tirzepatide 10 mg · £8,665 · tirzepatide 15 mg · £9,462 · Comparator is the 1 mg diabetes dose, not 2.4 mg.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A UK analysis divided annual pharmacy cost by the share of patients reaching a composite target, giving a cost per patient who actually responds rather than a cost per prescription.
-   At the strictest target — HbA1c ≤ 6.5%, weight loss ≥ 15%, no hypoglycemia — tirzepatide came in £5,650 to £9,462 lower per patient reaching it than semaglutide 1 mg.
-   The gap widened as targets got stricter, and reversed at the loosest target, where semaglutide 1 mg cost less per responder.
-   The analysis used semaglutide 1 mg in adults with type 2 diabetes. Both groups took metformin.

When judging [whether a GLP-1 is worth the cost](https://buythisglp.com/research/is-a-glp1-worth-the-cost), the monthly drug bill leaves out the chance of reaching the treatment goal. A UK analysis divided annual pharmacy cost by the proportion of patients who hit a composite target. The result estimates the cost per patient who reached that target [\[1\]](https://buythisglp.com/research/cost-per-patient-who-actually-hits-target#ref-1).

The targets combined glycemic control at two thresholds with weight loss at 5%, 10% or 15%, and required avoiding hypoglycemia. Response rates came from a post-hoc cut of the SURPASS-2 trial (n = 1,845), in which both groups took metformin. The analysis used UK pharmacy prices, including the tirzepatide costs NICE appraised in TA924. At the strictest combination, HbA1c at or below 6.5% with weight loss of at least 15% and no hypoglycemia, tirzepatide cost £5,650, £8,665 and £9,462 less per patient reaching it at the 5, 10 and 15 mg doses respectively.

The pattern inside that result is more interesting than the headline. Differences grew as targets got stricter, which is what happens when one drug produces more large responses: the denominator shrinks faster for the weaker performer. And the pattern reversed at the loosest target, where HbA1c below 7.0% with 5% weight loss and no hypoglycemia was cheaper per responder on semaglutide [\[1\]](https://buythisglp.com/research/cost-per-patient-who-actually-hits-target#ref-1). The cost per responder depends on which endpoint the analysis uses.

The comparator is the 1 mg dose

The study compared tirzepatide with semaglutide 1 mg in people with type 2 diabetes. It gives no estimate for semaglutide 2.4 mg in a weight-management population [\[1\]](https://buythisglp.com/research/cost-per-patient-who-actually-hits-target#ref-1).

The figures use UK pharmacy costs, including the tirzepatide prices appraised by NICE. They cannot tell a U.S. patient what they would pay. Several authors list Eli Lilly affiliations, and the results rely on a post hoc analysis of a single trial [\[1\]](https://buythisglp.com/research/cost-per-patient-who-actually-hits-target#ref-1).

The [tirzepatide lifetime cost model](https://buythisglp.com/research/tirzepatide-lifetime-cost-model) asks a longer-term question than this trial-based comparison. Read the assumptions before using its projections to compare costs.

A separate [study of tirzepatide and semaglutide at other doses](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses) measured short-term weight change. An analysis of [cost per quality-adjusted life year](https://buythisglp.com/research/is-semaglutide-cost-effective-for-mash) illustrates how economic models can account for both length and quality of life.

## Frequently asked

What is a cost-to-target analysis?

It divides the annual cost of a drug by the share of patients who reach a defined treatment goal, giving a cost per patient who actually responds instead of a cost per prescription.

Is this a fair comparison between the two drugs?

The analysis compares the doses used in SURPASS-2 in adults with type 2 diabetes. Its cost-per-responder estimates apply to semaglutide 1 mg and the three tirzepatide doses studied.

Do these pound figures mean anything for a US buyer?

No. They are UK pharmacy costs at prices appraised by NICE, which bear no relation to US cash prices. The method is transferable; the amounts are not.

## Sources

1.  \[1\] Kanumilli N, Osumili B, Evans J, Webb J, et al. (2026). Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK Journal of Medical Economics. [PMID 41771166](https://pubmed.ncbi.nlm.nih.gov/41771166/)

## Where to get it

### The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

[See the board →](https://buythisglp.com/best/cheapest-glp1)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
